Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors (SABR-DETECT)

• Published in: Clinical lung cancer Vol. 25; no. 2; pp. e87 - e91
• Main Authors: Verma, Saurav, Young, Sympascho, Kennedy, Thomas A.C., Carvalhana, Ilda, Black, Morgan, Baer, Kathie, Churchman, Emma, Warner, Andrew, Allan, Alison L., Izaguirre-Carbonell, Jesus, Dhani, Harmeet, Louie, Alexander V., Palma, David A., Breadner, Daniel A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2024
• Subjects: Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - radiotherapy; Circulating Tumor DNA; ctDNA; Early-stage; Humans; Liquid biopsy; Lung cancer; Lung Neoplasms - diagnosis; Lung Neoplasms - genetics; Lung Neoplasms - radiotherapy; Neoplasm Staging; Non–small-cell lung cancer; NSCLC; Radiosurgery - methods; Treatment Outcome; Non–small-cell lung cancer; Liquid biopsy; Early-stage; NSCLC; Lung cancer; ctDNA
• ISSN: 1525-7304; 1938-0690
• DOI: 10.1016/j.cllc.2023.11.013

For patients with stage I/IIA non–small-cell lung cancer (NSCLC), surgical resection is the standard treatment. However, some of these patients are not candidates for surgery or refuse a surgical option. Definitive stereotactic ablative radiotherapy (SABR) is a standard approach in these patients. Approximately 15% of patients undergoing SABR for localized NSCLC will experience a recurrence within 2 years. Furthermore, many of these patients are deemed appropriate for SABR without a tissue diagnosis, based on the likelihood of malignancy which can be calculated by validated models. A liquid biopsy, detecting ctDNA, would be useful in early detection of recurrences, and documenting a cancer diagnosis in patients without a biopsy. This is a multi-institutional study enrolling patients with suspected stage I/IIA NSCLC and a pretreatment likelihood of malignancy of ≥60% using the validated models for patients without a tissue diagnosis, in cohort 1 (n = 45). The second cohort will consist of biopsied patients (n = 30-60). SABR will be delivered as per risk-adapted protocol. Plasma will be collected for ctDNA analysis prior to the first fraction of SABR, 24 to 72 hours after first fraction, and at 3, 6, 9, 12, 18, and 24-months. The patients will be followed up with imaging at 3, 6, 9, 12, 18, and 24-months. The primary objective is to assess whether a cancer detection liquid biopsy platform can predict recurrence of NSCLC. The secondary objectives are to assess the impact of SABR on detection rates of ctDNA in patients undergoing SABR and to correlate ctDNA positivity and pretreatment probability of malignancy (NCT05921474).